FDA Warns of ADHD Drug Risks for Young Children; Parents Urged to Monitor Weight Loss

Young children prescribed extended-release ADHD medications may face increased risks of weight loss and other side effects, according to a new directive from the U.S. Food and Drug Administration. While these drugs are not approved for use in children under six, they are sometimes prescribed off-label. The FDA now requires drug manufacturers to update their labeling to reflect higher plasma exposure and adverse reaction rates in this age group.

The updated safety guidance applies to all extended-release stimulants containing amphetamine or methylphenidate, commonly used to treat attention-deficit/hyperactivity disorder (ADHD). These medications are considered first-line treatments for ADHD but carry particular risk for younger children. To standardize the messaging, the FDA is mandating a “Limitation of Use” section in the drug labeling for any product lacking one, and updates to existing sections to ensure consistent warnings across the category.

While these drugs are not officially approved for patients under six years old, doctors may prescribe them off-label. The FDA urges health care professionals to closely monitor younger children who are prescribed these medications. Medical providers are encouraged to consider alternative treatments, such as immediate-release stimulants, which are approved for younger patients, or behavioral therapies as needed.

Parents and guardians are advised to watch for signs of weight loss and to consult with their child’s health care provider to evaluate whether to continue, adjust, or stop the medication. Decisions should be made based on a child’s individual response and health status. Physicians are also reminded to track a child’s growth and development during treatment and intervene when necessary to reduce the risk of adverse effects.

Article by multiple contributors, based upon information from the U.S. Food and Drug Administration press release

---